SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-16-114959
Filing Date
2016-04-28
Accepted
2016-04-28 09:13:08
Documents
13
Period of Report
2015-12-31

Document Format Files

Seq Description Document Type Size
1 20-F a16-9359_120f.htm 20-F 3929864
2 EX-1.2 a16-9359_1ex1d2.htm EX-1.2 22563
3 EX-1.3 a16-9359_1ex1d3.htm EX-1.3 39425
4 EX-4.12 a16-9359_1ex4d12.htm EX-4.12 21072
5 EX-8.1 a16-9359_1ex8d1.htm EX-8.1 4141
6 EX-12.1 a16-9359_1ex12d1.htm EX-12.1 9347
7 EX-12.2 a16-9359_1ex12d2.htm EX-12.2 9378
8 EX-13.1 a16-9359_1ex13d1.htm EX-13.1 8570
9 EX-15.1 a16-9359_1ex15d1.htm EX-15.1 5313
10 GRAPHIC g93591fci001.jpg GRAPHIC 1675
11 GRAPHIC g93591boi001.jpg GRAPHIC 37742
12 GRAPHIC g93591boi002.jpg GRAPHIC 8487
13 GRAPHIC g93591lsi001.jpg GRAPHIC 2688
  Complete submission text file 0001104659-16-114959.txt   4120882
Mailing Address LEBERSTRASSE 20 VIENNA C4 1110
Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0
Nabriva Therapeutics AG (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: C4 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-37558 | Film No.: 161597384
SIC: 2834 Pharmaceutical Preparations